Please login to the form below

Not currently logged in
Email:
Password:

nivolumab

This page shows the latest nivolumab news and features for those working in and with pharma, biotech and healthcare.

Merck’s Keytruda meets survival challenge in NSCLC

Merck’s Keytruda meets survival challenge in NSCLC

It’s another win for Merck in this treatment space over rival Bristol-Myers Squibb, whose PD-1 inhibitor Opdivo (nivolumab) has struggled to find purchase in first-line NSCLC after

Latest news

More from news
Approximately 63 fully matching, plus 196 partially matching documents found.

Latest Intelligence

  • Accelerating innovation Accelerating innovation

    Leading this work is an agreement with Bristol-Myers Squibb to study a combination of Cabometyx and that firm’s blockbuster immuno-oncology drug Opdivo (nivolumab) and an agreement with Roche

  • Managed Access Programmes: a powerful source of real-world insight Managed Access Programmes: a powerful source of real-world insight

    Quadrini S, Antonelli P, Manzo A, Prediletto I, Giannarelli D, Galetta D; Italian cohort of nivolumab Expanded Access Programme (EAP): preliminary data from a real-world population.

  • Managed Access Programmes: a powerful source of real-world insight Managed Access Programmes: a powerful source of real-world insight

    Quadrini S, Antonelli P, Manzo A, Prediletto I, Giannarelli D, Galetta D; Italian cohort of nivolumab Expanded Access Programme (EAP): preliminary data from a real-world population.

  • Deal Watch September 2016 Deal Watch September 2016

    A clinical co-operation between Bristol-Myers Squibb and Nektar Therapeutics was closed under which Opdivo [nivolumab] will be evaluated in combination with Nektar's NKTR-214 in phase I/II

  • Pharma deals in February 2015 Pharma deals in February 2015

    As well as the already marketed Yervoy (ipilimumab) and recently FDA approved Opdivo (nivolumab), BMS has four additional immuno-oncology drugs in clinical trial.

More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest appointments

  • BMS appoints oncology development head BMS appoints oncology development head

    On moving to the US in 2006, Dr Namouni took over responsibility for metastatic colorectal cancer treatment Erbitux (cetuximab), before serving as development lead for Opdivo (nivolumab) and Yervoy (ipilimumab).

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Apex.co.uk Conferences, Events and Exhibition Stands

Apex.co.uk is one of the UK’s leading event and exhibition agencies, specialising in healthcare. We understand your communication goals, whether...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics